Literature DB >> 30877106

Combined Menin and EGFR Inhibitors Synergize to Suppress Colorectal Cancer via EGFR-Independent and Calcium-Mediated Repression of SKP2 Transcription.

Bryson W Katona1,2, Rebecca A Glynn2, Kayla E Paulosky2, Zijie Feng2, Caroline I Davis3, Jian Ma2, Corbett T Berry4,5, Katherine M Szigety2, Smita Matkar2, Yuanyuan Liu2, Haoren Wang2, Yuan Wu2,6, Xin He2, Bruce D Freedman4, Donita C Brady2, Xianxin Hua7.   

Abstract

Menin is a nuclear epigenetic regulator that can both promote and suppress tumor growth in a highly tissue-specific manner. The role of menin in colorectal cancer, however, remains unclear. Here, we demonstrate that menin was overexpressed in colorectal cancer and that inhibition of menin synergized with small-molecule inhibitors of EGFR (iEGFR) to suppress colorectal cancer cells and tumor xenografts in vivo in an EGFR-independent manner. Mechanistically, menin bound the promoter of SKP2, a pro-oncogenic gene crucial for colorectal cancer growth, and promoted its expression. Moreover, the iEGFR gefitinib activated endoplasmic reticulum calcium channel inositol trisphosphate receptor 3 (IP3R3)-mediated release of calcium, which directly bound menin. Combined inhibition of menin and iEGFR-induced calcium release synergistically suppressed menin-mediated expression of SKP2 and growth of colorectal cancer. Together, these findings uncover a molecular convergence of menin and the iEGFR-induced, IP3R3-mediated calcium release on SKP2 transcription and reveal opportunities to enhance iEGFR efficacy to improve treatments for colorectal cancer. SIGNIFICANCE: Menin acts as a calcium-responsive regulator of SKP2 expression, and small molecule EGFR inhibitors, which induce calcium release, synergize with Menin inhibition to reduce SKP2 expression and suppress colorectal cancer. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30877106      PMCID: PMC6996413          DOI: 10.1158/0008-5472.CAN-18-2133

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  Effect of secretagogues on cytoplasmic free calcium in alveolar type II epithelial cells.

Authors:  K Sano; D R Voelker; R J Mason
Journal:  Am J Physiol       Date:  1987-11

Review 2.  Mitochondrial and endoplasmic reticulum calcium homeostasis and cell death.

Authors:  Saverio Marchi; Simone Patergnani; Sonia Missiroli; Giampaolo Morciano; Alessandro Rimessi; Mariusz R Wieckowski; Carlotta Giorgi; Paolo Pinton
Journal:  Cell Calcium       Date:  2017-05-05       Impact factor: 6.817

3.  Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells.

Authors:  Silvia Carloni; Francesco Fabbri; Giovanni Brigliadori; Paola Ulivi; Rosella Silvestrini; Dino Amadori; Wainer Zoli
Journal:  Curr Cancer Drug Targets       Date:  2010-06       Impact factor: 3.428

Review 4.  The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer.

Authors:  Ovidiu V Bochis; Alexandru Irimie; Martin Pichler; Ioana Berindan-Neagoe
Journal:  J Gastrointestin Liver Dis       Date:  2015-06       Impact factor: 2.008

5.  A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer.

Authors:  Mary J Mackenzie; Holger W Hirte; Goss Glenwood; Maroun Jean; Rakesh Goel; Pierre P Major; Wilson H Miller; Lawrence Panasci; Ian A J Lorimer; Gerald Batist; Sarah Matthews; Lynn Douglas; Lesley Seymour
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

6.  CDK9 is constitutively expressed throughout the cell cycle, and its steady-state expression is independent of SKP2.

Authors:  Judit Garriga; Sabyasachi Bhattacharya; Joaquim Calbó; Renée M Marshall; May Truongcao; Dale S Haines; Xavier Graña
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

7.  Correlation of Skp2 with carcinogenesis, invasion, metastasis, and prognosis in colorectal tumors.

Authors:  Jia-Qing Li; Fei Wu; Tsutomu Masaki; Akihito Kubo; Jiro Fujita; Dan A Dixon; R Daniel Beauchamp; Toshihiko Ishida; Shigeki Kuriyama; Katsumi Imaida
Journal:  Int J Oncol       Date:  2004-07       Impact factor: 5.650

Review 8.  Mechanism of action and persistence of neuroprotection by cell-permeant Ca2+ chelators.

Authors:  M Tymianski; I Spigelman; L Zhang; P L Carlen; C H Tator; M P Charlton; M C Wallace
Journal:  J Cereb Blood Flow Metab       Date:  1994-11       Impact factor: 6.200

9.  Comprehensive molecular characterization of human colon and rectal cancer.

Authors: 
Journal:  Nature       Date:  2012-07-18       Impact factor: 49.962

Review 10.  Histone Deacetylase Inhibitors as Anticancer Drugs.

Authors:  Tomas Eckschlager; Johana Plch; Marie Stiborova; Jan Hrabeta
Journal:  Int J Mol Sci       Date:  2017-07-01       Impact factor: 5.923

View more
  9 in total

1.  Functional genetic screen identifies ITPR3/calcium/RELB axis as a driver of colorectal cancer metastatic liver colonization.

Authors:  Ryan H Moy; Alexander Nguyen; Jia Min Loo; Norihiro Yamaguchi; Christina M Kajba; Balaji Santhanam; Benjamin N Ostendorf; Y Gloria Wu; Saeed Tavazoie; Sohail F Tavazoie
Journal:  Dev Cell       Date:  2022-04-28       Impact factor: 13.417

2.  Disruption of the menin-MLL interaction triggers menin protein degradation via ubiquitin-proteasome pathway.

Authors:  Yuan Wu; Miriam Doepner; Taylor Hojnacki; Zijie Feng; Bryson W Katona; Xin He; Jian Ma; Yan Cao; Luca Busino; Fuxiang Zhou; Xianxin Hua
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

3.  Menin-regulated Pbk controls high fat diet-induced compensatory beta cell proliferation.

Authors:  Jian Ma; Bowen Xing; Yan Cao; Xin He; Kate E Bennett; Chao Tong; Chiying An; Taylor Hojnacki; Zijie Feng; Sunbin Deng; Sunbin Ling; Gengchen Xie; Yuan Wu; Yue Ren; Ming Yu; Bryson W Katona; Hongzhe Li; Ali Naji; Xianxin Hua
Journal:  EMBO Mol Med       Date:  2021-04-06       Impact factor: 12.137

4.  Menin: Expanding and dichotomous roles in cancer.

Authors:  Bryson W Katona; Rebecca A Glynn; Taylor A Hojnacki; Xianxin Hua
Journal:  Oncoscience       Date:  2019-08-23

5.  Cdh1-mediated Skp2 degradation by dioscin reprogrammes aerobic glycolysis and inhibits colorectal cancer cells growth.

Authors:  Li Zhou; Xinfang Yu; Ming Li; Guanghui Gong; Wenbin Liu; Tian Li; Huilan Zuo; Wei Li; Feng Gao; Haidan Liu
Journal:  EBioMedicine       Date:  2019-12-02       Impact factor: 8.143

6.  The CK1δ/ε-AES axis regulates tumorigenesis and metastasis in colorectal cancer.

Authors:  Zhongyuan Wang; Liang Zhou; Yejun Wang; Quanzhou Peng; Huan Li; Xin Zhang; Zijie Su; Jiaxing Song; Qi Sun; Sapna Sayed; Shanshan Liu; Desheng Lu
Journal:  Theranostics       Date:  2021-03-04       Impact factor: 11.556

7.  The Prognostic and Molecular Landscape of Autophagy-Related Long Noncoding RNA in Colorectal Cancer.

Authors:  YuanLin Sun; XueYuan Cao; YuChen Guo; Bin Liu; Yang Zhang
Journal:  Biomed Res Int       Date:  2022-01-20       Impact factor: 3.411

8.  Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression.

Authors:  Ching-Chan Lin; Yu-Kai Huang; Chia-Fong Cho; Yu-Sen Lin; Chia-Chien Lo; Ting-Ting Kuo; Guan-Chin Tseng; Wei-Chung Cheng; Wei-Chao Chang; Tzu-Hung Hsiao; Liang-Chuan Lai; Jin-Yuan Shih; Yu-Huei Liu; K S Clifford Chao; Jennifer L Hsu; Pei-Chih Lee; Xian Sun; Mien-Chie Hung; Yuh-Pyng Sher
Journal:  Theranostics       Date:  2020-08-29       Impact factor: 11.556

9.  Menin-mediated Repression of Glycolysis in Combination with Autophagy Protects Colon Cancer Against Small-molecule EGFR Inhibitors.

Authors:  Bryson W Katona; Taylor Hojnacki; Rebecca A Glynn; Kayla E Paulosky; Katherine M Szigety; Yan Cao; Xuyao Zhang; Zijie Feng; Xin He; Jian Ma; Xianxin Hua
Journal:  Mol Cancer Ther       Date:  2020-09-02       Impact factor: 6.261

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.